STAT+: HHS rebukes drug makers for curtailing discounts to hospitals that serve low-income communities
After months of controversy, the Department of Health and Human Services issued a stern rebuke to several large drug makers that have sought to curtail the discounts they offer through a federal program for safety-net hospitals and clinics.
At issue is the 340B drug discount program, which requires drug makers to offer discounts that are typically estimated to be 25% to 50% — but could be much higher — on all outpatient drugs to hospitals and clinics that serve low-income populations. There are approximately 12,400 so-called covered entities, including 2,500 hospitals, participating in the program.
Continue to STAT+ to read the full story…
